Loading…
← CockpitCompetitor Analysis › 002030.SZ Daan Gene Co., Ltd. Class AOpen in the cockpit ↗

Daan Gene Co., Ltd. Class A002030.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese molecular-diagnostics company making PCR-based test kits for infectious diseases, affiliated with Sun Yat-sen University.

≈ A Chinese Roche Diagnostics/Hologic for molecular testingMomentum strong 67
Mkt cap
$1.05B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$11.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-11.3 pp
WACC 6.2%
Hurdle
+37 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥5.04
1D-0.4%
1W-5.1%
1M-8.7%
3M-10.9%
6M-16.6%
YTD-15.4%
1Y-23.3%
ATR %3.1%
52w lowhigh38.5% off high

What Daan Gene does

Chinese molecular-diagnostics company making PCR-based test kits for infectious diseases, affiliated with Sun Yat-sen University.

Sells PCR test kits and the instruments that read them, mainly to hospitals and clinical labs, where kits are used up with each test, so ongoing sales follow testing volume. COVID-19 testing briefly dominated demand and has since faded, returning focus to hepatitis B and HPV and other routine infection tests.

In one line: A Chinese Roche Diagnostics/Hologic for molecular testing.

Products and services

  • PCR infectious-disease test kits (HBV, HPV, COVID)
  • Diagnostic instruments

Customers

  • Hospitals
  • Clinical labs
  • CDC

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics
  • Molecular/PCR testing

What could go right

  • Molecular diagnostics adoption growth

What could go wrong

  • Post-COVID testing demand decline
  • Price competition

Moat: narrow (regulatory licence, IP / patents, brand). Early mover and established brand in China's PCR molecular-diagnostics market.

Headquarters: Guangzhou, China · Employees: 1,506

Named competitors

Daan Gene at a glance

Size Daan Gene (002030.SZ) is a China Health Care company (Biotechnology) with a market value of $1.05B, the 2063rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.04 on 18 Nov 2026.

Performance Over six months the shares fell 16.6%, against -18.5% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 1.4% over the last twelve months (peer median +0.2%); the operating margin is -81.3% (peer median -2.5%).

Valuation It trades at 8.0× enterprise value to sales against a peer median of 5.6× (6th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -32%, so the hurdle is +37 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.3 points below its cost of capital (6.2% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 83002030.SZ 76
Six months, rebased to 100: Daan Gene against the median of its 20 peers (local-currency closes).

Daan Gene financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥776MCN¥757MCN¥851MCN¥1.18BCN¥12.0B
Revenue growth—-11%-28%-90%—
Gross profitCN¥400MCN¥110MCN¥171MCN¥441MCN¥8.56B
EBITDAn/a-CN¥180M-CN¥361MCN¥3.60MCN¥6.45B
Net income-CN¥743M-CN¥744M-CN¥925MCN¥105MCN¥5.41B
Free cash flowCN¥276MCN¥110MCN¥155MCN¥273MCN¥2.70B
Capital expenditureCN¥110MCN¥239MCN¥174MCN¥573MCN¥1.50B
Total debtCN¥129MCN¥140MCN¥173MCN¥373MCN¥236M

Quarterly statements and history in the cockpit →

Daan Gene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%3004829606ANROJBIOINBXVORSGP688276CMPS600195AKUMS688253ODTX300841MLYS6887392160301207002030.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Daan Gene is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×3004829606INBX688276AKUMS688253ODTX6887392160002030.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Daan Gene is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%300482600195AKUMS688253300841688739301207002030.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Daan Gene is the large dot.

Daan Gene competitors and peer comparison

Head to head with its named competitors (002030.SZ vs 300676.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Daan Gene 002030.SZ$1.05B-17%+1%-81%8.0×4.8%
BGI Genomics 300676.SZ$2.13B-15%0%-14%3.2×n/a

How Daan Gene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Daan Gene against its 20 peers (data as of 18 Nov 2026)
Measure002030.SZPeer medianRank in peer set
1-month return-8.7%-8.7%11th highest of 21
6-month return-16.6%-18.5%10th highest of 20
Distance from 52-week high-38.5%-41.8%9th highest of 21
Revenue growth (TTM)+1.4%+0.2%6th highest of 14
Operating margin-81.3%-2.5%4th lowest of 14
EV / Sales8.0×5.6×6th most expensive of 14
Growth the price implies (Req g, 7 yrs)4.8%14.3%least demanding of 8
Growth delivered (Del g)-32.3%-5.8%lowest of 8
Hurdle (Req g minus delivered)+37.0 pp+13.6 pp3rd most demanding of 8
ROIC minus cost of capital-11.3 pp-5.6 pp5th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%

Questions

Who are Daan Gene's main competitors?
Named competitors: BGI Genomics (300676.SZ), Roche Diagnostics (private or unlisted). The cockpit's measured peer set (industry) also includes Guangzhou Wondfo Biotech (300482.SZ), Duality Biotherapeutics (9606.HK), Alto Neuroscience (ANRO), Jade Biosciences (JBIO), Inhibrx Biosciences (INBX), Vor Biopharma (VOR).
Is Daan Gene expensive compared with its peers?
On ev / sales it trades at 8.0× against a peer median of 5.6×, 6th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -32%, so the hurdle is +37 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Daan Gene stock performed?
Over six months to 18 Nov 2026 the shares returned -16.6% against -18.5% for the median peer; over one year -23.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.